Pneumonia News and Research

Latest Pneumonia News and Research

Contaminant particles emitted by vehicles have negative repercussions in children with respiratory illnesses

Particles of less than 2.5 microns emitted by vehicles have negative repercussions for bronchiolitis, pneumonia, asthma and bronchitis in children.

1 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

1 Jun 2015

UT Southwestern Medical Center Performs its 500th Lung Transplant on Cystic Fibrosis Patient

A lung transplant to relieve Christopher Bryant Vera from devastating effects of cystic fibrosis marked the 500th lung transplant performed at UT Southwestern Medical Center, positioning the Center among an elite group of fewer than 25 in the country to achieve that benchmark.

30 May 2015

UB researchers successfully harness E. coli to generate new forms of antibiotics

Like a dairy farmer tending to a herd of cows to produce milk, researchers are tending to colonies of the bacteria Escherichia coli (E. coli) to produce new forms of antibiotics -- including three that show promise in fighting drug-resistant bacteria.

30 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Actavis creates collaborative program to improve care for patients with multidrug-resistant infections

Actavis plc, a leading global specialty pharmaceutical company committed to infectious disease treatment innovation, today announced the creation of SHARE ID (Sharing Hospital data to Advance Research and Enhance patient care in Infectious Diseases), a collaborative program to leverage real-world data to advance the delivery and effectiveness of care for patients with serious infections due to antibiotic-resistant pathogens.

27 May 2015

Existing anti-stroke drug can be effective in treating middle-ear infections

An existing anti-stroke drug is an effective treatment for middle-ear infections, showing the ability to suppress mucus overproduction, improve bacterial clearance and reduce hearing loss, according to researchers at Georgia State University and the University of Rochester.

21 May 2015

ICS use may lower risk of mortality from pneumonia and other causes in COPD patients

Treatment of COPD with inhaled corticosteroids (ICS) may decrease the risk of dying from pneumonia and from other causes despite being associated with an increase in the occurrence of pneumonia, according to a new meta-analysis presented at the 2015 American Thoracic Society International Conference.

21 May 2015

Second-generation antibiotic shows promise against common bacterial infections

Researchers led by St. Jude Children's Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults.

21 May 2015

Kidney function plays critical role in sepsis patients

Researchers at Duke Medicine have determined that kidney function plays a critical role in the fate of patients being treated for sepsis, a potentially life-threatening complication of an infection.

21 May 2015

Toxin pneumolysin causes progressive and fatal heart complications

Streptococcus pneumoniae is a major human pathogen and is known to be associated with increased risk of fatal heart complications including heart failure and heart attacks.

19 May 2015

No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

There is little reliable evidence that electronic cigarettes are effective for long-term smoking cessation, according to a new analysis of the currently available research which was presented at the 2015 American Thoracic Society International Conference.

18 May 2015

Bronchitis can cause pneumonia, says Loyola physician

When a cold has lasted too long or a cough is especially bothersome, it's important to see a medical professional.

14 May 2015

WHO Press Release: World Health Statistics reports on global health goals for 194 countries

Progress in child survival worldwide is one of the greatest success stories of international development. Since 1990, child deaths have almost halved – falling from an estimated 90 deaths per 1000 live births to 46 deaths per 1000 live births in 2013...

13 May 2015

Pneumonia News and Research

Latest Pneumonia News and Research

Contaminant particles emitted by vehicles have negative repercussions in children with respiratory illnesses

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

UT Southwestern Medical Center Performs its 500th Lung Transplant on Cystic Fibrosis Patient

UB researchers successfully harness E. coli to generate new forms of antibiotics

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Actavis creates collaborative program to improve care for patients with multidrug-resistant infections

Existing anti-stroke drug can be effective in treating middle-ear infections

ICS use may lower risk of mortality from pneumonia and other causes in COPD patients

Second-generation antibiotic shows promise against common bacterial infections

Kidney function plays critical role in sepsis patients

Toxin pneumolysin causes progressive and fatal heart complications

No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

Bronchitis can cause pneumonia, says Loyola physician

WHO Press Release: World Health Statistics reports on global health goals for 194 countries

Industry Focus: Cell & Gene Therapy eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Pneumonia News and Research

Latest Pneumonia News and Research

Industry Focus: Cell & Gene Therapy eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in